subscribeSubscribe
FTC says patent battle over Parkinson`s drug have `significant implications`

FTC says patent battle over Parkinson`s drug have `significant implications`
Nicole DeFeudis ENDPTS
21 Mar 2023
Share Share
Enforcement Report - Week of February 1, 2023

Enforcement Report - Week of February 1, 2023
FDA
01 Feb 2023
Share Share
FDA rejects Supernus’ drug infusion device for Parkinson’s

FDA rejects Supernus’ drug infusion device for Parkinson’s
Delilah Alvarado BIOPHARMADIVE
11 Oct 2022
Share Share
Celera`s apomorphine therapy device for Parkinson’s set as alternative to DBS

Celera`s apomorphine therapy device for Parkinson’s set as alternative to DBS
PHARMABIZ
09 Mar 2022
Share Share
TruPharma Announces Approval and Launch of Apomorphine Hydrochloride Cartridges

TruPharma Announces Approval and Launch of Apomorphine Hydrochloride Cartridges
PRNEWSWIRE
01 Mar 2022
Share Share
Sage Pharms` Generic Apomorphine Hydrochloride Receives Approval in the U.S.

Sage Pharms` Generic Apomorphine Hydrochloride Receives Approval in the U.S.
FDA
23 Feb 2022
Share Share
Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830

Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830
GLOBENEWSWIRE
22 Feb 2022
Share Share
Sunovion and BIAL Enter European Licensing Agreement

Sunovion and BIAL Enter European Licensing Agreement
BUSINESSWIRE
02 Sep 2021
Share Share
Sunovion Announces the Commercial Launch of KYNMOBI™

Sunovion Announces the Commercial Launch of KYNMOBI™
BIOSPACE
03 Oct 2020
Share Share
Sunovion Announces Health Canada Approval of KYNMOBI™

Sunovion Announces Health Canada Approval of KYNMOBI™
BIOSPACE
15 Jun 2020
Share Share